Emerging Concepts In Treating Onychomycosis

John D. Mozena, DPM, and Joshua P. Mitnick, DPM


1. Mozena JD. A guide to treatments for onychomycosis. Podiatry Today 2003; 16(8):61-68.
2. Mozena JD. Why onychomycosis can no longer be dismissed as a cosmetic problem. Podiatry Today 2000; 13(2):29-34.
3. Charis MA, Elewski BE. Historical perspective on onychomycosis. Dermatological Therapy 1997; 3:43.
4. Trepanier EF, Amsden GW. Current issues on onychomycosis. Ann Pharmacol 1998; 32(2)204-14.
5. Fishman HC. Practical therapy for ingrown toenails. Cutis 1983; 32(2):159-60.
6. Gonzalez-Serva A. Structure and function. In: Scher RK, Daniel CR (eds). Nails, therapy diagnosis, surgery. W.B. Saunders Co., Philadelphia, chapter 2, pp. 13, 1990.
7. Joseph WS. Oral treatment options for onychomycosis. JAPMA 1997; 87(11):520-31.
8. Joseph WS, Mozena JD. Podiatric approach to onychomycosis. In: Scher RK, Daniel CR(eds). Nails: diagnosis, therapy, surgery, 3rd Edition. Elsevier Saunders, 2005, chapter 18, pp. 133-140.
9. Penlac FM Nail Lacquer (package insert). Dermik Laboratories, Inc., Berwyn, Pa., 2000.
10. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43(4 Suppl):S70-S80.
11. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001; 68(2 Suppl):17-22.
12. Available from: http//www.anacor.com/an2690.php
13. Boker A, Bae YS, Gowrishankar TR, et al. A double-blind, placebo-controlled pilot study of 1% terbinafine cream delivered via toenail microconduits for the treatment of subungual onychomycosis. Poster presented at the 65th annual meeting of the American Academy of Dermatology, Washington, DC, Feb. 2-6, 2007.
14. Jones T, Ijzerman, Flack M, Baker JR. Tolerability, safety and pharmacokinetics of topical nanoemulsion (NB-002) in patient with onychomycosis. Poster presented at Interscience conference on antimicrobial agents and chemotherapy, 17-20 Sept. 2007, Chicago, IL, USA
15. Available from: http://www.medicalnewstoday.com/articles/116086.php
16. Itraconazole (package insert). Ortho-McNeil, Raritan, NJ, 2009.
17. Gupta AK. Management options in onychomycosis. Am J Sports Med 2000; 28(2):118.
18. Elewski B. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993; 28(5 Pt 1):S28-S34.
19. Terbinafine (package insert). Medical Economics Company, Inc., Montvalle, NJ, 1999.
20. Kumar S, Kimball A. New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs 2009; 18(6):727-734.
21. Geria AN, Scheinfeld NS. Pramiconazole, a triazole compound for the treatment of fungal infections. IDrugs 2008; 11(9):661-70.
22. Available from: www.nomirmedical.com/news2.pdf
23. Available from: www.nomirmedical.com/news1.pdf
24. Available from: www.patholase.com/news/multi-center-trial
25. Arpida reports progress in pivotal Phase III trial with TLT treat treatment in onychomycosis. Available from: www.arpida.ch/1/content/arpida-tlt-phiii.pdf
26. Boker A, Cumbie B, Kimball AB. A single-center, prospective, open-label, pilot study of the safety, local tolerability, and efficacy of ultraviolet-C (UVC) phototherapy for the treatment of great toenail onychomycosis. Poster presented at the World Congress of Dermatology, Buenos Aires, Argentina, Sept. 30-Oct. 5, 2007.
27. Dai T, Tegos GP, Rolz-Cruz G, Cumbie WE, Hamblin MR. Ultraviolet C inactivation of dermatophytes: implications for treatment of onychomycosis. Br J Dermatol 2008 Jun; 158(6):1239-46.
28. Available from: www.talima.com/technology.html
29. Correspondence with Todd Weinfield, CEO, Innovation Biomedical Devices, Inc., 2009.


For professionals in the Podiatric community that are interested, here is the current Pivotal Study information on the Noveon from Nomir Medical Technologies

There were 36 subjects (53 Toes) enrolled in the study.

Starting after the completion of the second of the four treatments, all subjects were required to use a non-prescriptive topical agent: 1% topical terbinafine cream applied only between the toes to control or prevent tinea interdigitalis.

Patients were instructed to not get any cream on the nails.

Use of this topical between the toes only, was in accordance with the current listed product information and is neither FDA indicated, nor FDA cleared as a treatment for onychomycosis. Other adjunctive actions that are "standard of care", such as nail debridement or nail trimming, were allowed at each investigator’s discretion.

Control subjects were handled identically in all respects to those who were treated, except for, of course, with sham “treatment” there was no energy delivery. The highest treatment site temperature was 100.5°F.

All study subjects had to have laboratory confirmation of onychomycosis by either positive culture using a selective dermatophyte test medium, or positive periodic acid-Schiff staining (PAS) from a toenail sample.

The mycology was followed and data taken for the 180 day balance of the study.

The top-line preliminary 120-day data analysis that was presented at the Council for Nail Disorders 13th Annual Scientific Meeting, and demonstrated that after Noveon treatment, 76.3 percent of the treated toes showed evidence of clinical improvement (p

This data was based on at least 120 days of follow-up on all enrolled patients. Additionally, no significant adverse events were reported.

The final 180 day data, is currently under review by the FDA in an application for 510(k) approval for Onychomycosis treatment, and has been accepted for publication with a Podiatric peer-review journal.

Completed pilot study data with this device can be found at:

Bornstein, E.S., A.H. Robbins, M. Michelon (2008) Photo-inactivation of fungal pathogens that cause onychomycosis in vitro and in vivo with the noveon dual wavelength laser system. 2008 New Cardiovascular Horizons Meeting Abstracts.


A lengthy discussion on this and other light-based onychomycosis technologies can be found at:


Eric Bornstein
Chief Science Officer
Nomir Medical Technologies

Add new comment